

**International Journal of Biology, Pharmacy
and Allied Sciences (IJBPAS)**

'A Bridge Between Laboratory and Reader'

www.jibpas.com

POTENTIAL ANTI SMOKING EFFECT BY USING IMIPRAMINE 25 mg DAILY

JUBRAN K. HASSAN*

* Department of Clinical Pharmacy, College of Pharmacy, University of Basra, Iraq

*Ph.D. Clinical Pharmacy – Department of Clinical Pharmacy, College of Pharmacy,
University of Basra, Basra City- Iraq

*Corresponding Author: E Mail: jubranhassan@gmail.com; Mobile: 09647709039681

Received 20th Aug. 2017; Revised 19th Sept. 2017; Accepted 30th October 2017; Available online 1st Feb. 2018

ABSTRACT

Purpose: This study explores the possible positive effect of imipramine on daily cigarettes smoking and if it may enforce stopping smoking during ten days by using 25mg once at night orally

Methods: Using placebo control study. In which adult smokers' volunteers were assigned to one of study groups; control (N=52) or Imipramine group (N=102). All volunteers take their medications as single daily dose at night and start to report number of cigarettes smoked daily for 10 days with reporting side effects appeared during the study.

Results: Imipramine group showed significant: declining in number of cigarettes daily smoked as compared with day1 of study and as compared with control group. 94.1 % of volunteers reduced daily smoking also 11.8 % of volunteers stop smoking at the end of study. Side effects reported in the study were drowsiness and headache and sleep disturbance.

Conclusions: Imipramine was effective to reduce number of daily cigarettes smoked and may help to stop this habit

Keywords: Imipramine, Antidepressant, tobacco, cigarettes smoking

INTRODUCTION

Smoking of Cigarettes consider one of global health problems, and one of leading causes of mortality in the world; [1] this led to many smoke control campaigns and

programs [2]. These programs offered help to stop smoking through forcing or encouraging cessation via behavioral therapy [3] and/or by pharmacological

means [4] with variable degree of success [4, 5]. This probably related to the complex effect of nicotine of cigarettes on CNS. Where Nicotine of cigarettes may affect release of many of neurotransmitters in various regions of brain; such neurotransmitters included dopamine, serotonin and glutamine [6, 7]. Also; it leads to change in level of MAO-A activity in brain leading to mood change [8]; In addition to addicting nature of nicotine presents in tobacco smoke [9]. These may be related to the variability in response to smoking cessation therapy.

Pharmacological therapy used for smoking cessation like bupropion, NRT, varenicline; Nortriptyline and cytosine have been shown to improve the chances of quitting. NRT or varenicline are equally effective as quitting aids. None of them was superior [10].

Stopping tobacco smoking may leads to depressive symptoms or causing a depressive episode [11, 12] that may be relieved by re smoking or its rationally could be ameliorated by using of antidepressants. Some antidepressants may affect some neural pathways already modulated by nicotine of cigarette [12] Clinical trials found that antidepressants like nortriptyline and bupropion may improve depression associated with stop smoking [12] and help a long-term smoking cessation; but with little number of serious

adverse effects. [12, 13] maintaining a long-term smoking cessation; may be independent of their antidepressant effect [12].

Imipramine (tofranil)[®] is one of efficient tricyclic antidepressants [14] that has many clinical uses; specially in controlling depression [14], neuropathic pain [15] and controlling enuresis [16]. It binds and affect large number of receptors and transmitters in brain like serotonin, [17] Norepinephrine, [18] dopamine [19], acetylcholine [20, 21] and others, like histamine [22]. This complexity in mode of action made it of interest for investigation the possibility of forcing smoking cessation in adults' smoker. **The Novelty** of this study; is that; the potential effect of imipramine in dose 25mg per day; at night on cigarettes smoking was not reported.

Aims of the study

Evaluate the potential positive effect of imipramine 25mg single daily dose before sleep on number of cigarettes smoked during 10 days trial; and if it leads to stop smoking

METHODS

Study design

The study was double blinded placebo control study

Study groups

Apparently healthy Adult smoker volunteers (smoker for \geq 1years &

age \geq 18years) are randomly assigned to one of the two groups of the study that include placebo control (N=51); study group (received imipramine 25mg single tablet before sleep) (N=102)

The study continued for ten days. Each volunteer received data collection form include name; telephone number, age, gender, type of cigarettes (trade name), quantity of nicotine and tar per cigarette and duration of smoking in years. Each volunteer received single daily dose of each drugs mentioned above as oral tablet; after signing of a written consent by each volunteer. Each volunteer was asked to report number of cigarettes smoked and appeared side effects at the end of each day of trial. Data collection form received from each volunteer after completion of ten days.

Data analysis: Data analyzed using Medcalc $\text{\textcircled{R}}$ software V12. Oneway Anova and T test was performed to find significant differences ($p<0.05$) between groups in age; years of smoking; nicotine and tar contents of cigars number of cigarettes smoked.

Chi square analysis was used to find the significant ($p<0.05$) differences in rate of smoking declining and percent of positive outcome between groups.

RESULTS

1- Age; smoking duration; Nicotine & Tar concentration per cigarettes

As in table1 there were no significant ($p<0.05$) differences in age (p value=0.923); average duration of smoking in years (p value= 0.2312); Nicotine concentration per cigarettes (p value= 0.0507) and finally tar concentration (p value= 0.6956).

2- Reported daily cigarettes smoking

As in Table 2, During the study, there was a significant ($p<0.05$) declining in number of daily cigarettes smoked by volunteers in Imipramine 25mg group (p value <0.0001 for imipramine Versus p value = 0.593 for control group); this declining was significant as compared with control group. (p value <0.0001). The changes in daily cigarettes smoking is clear in Figure 1.

At the 10th day of study there was significant ($p<0.05$) declining in number of cigarettes smoked as compared with day1, in Imipramine group (p value <0.0001). and this declining was also highly significant as compared with control value in day 10 of study (p value <0.0001) As in Table 3 & Figure 2.

3-Percent change in cigarettes smoking

As in Table 4 The average percentage of declining in cigarettes smoking was significantly greater in Imipramine group at

day 10 as compared with control value (-38 ± 35.1 vs. 5.87 ± 34.1 ; p value <0.0001). Also the total declining was significantly greater in imipramine group as compared with control (-20.95 ± 20.5 Vs. 7.33 ± 16.3 ; P value <0.0001).

4- Percent of positive outcome

As in Table 5; significantly ($p < 0.0001$) greater percentage of volunteers have positive outcome (measured as declining in number of cigarettes smoked) was in the imipramine group as compared with control group: where it was in day 10th (97.1% VS. 60.8% control) and when total change was measured (94.1% VS. 23.5% control).

11.8% of volunteers received imipramine have stopped smoking at the end of study; this ratio was significantly higher than

control value (p value = 0.0256). Odd ratio was high and favors imipramine group (Odd ratio = 52; 95% CI 18.228 to 148.345 and P value <0.0001).

4- The reported side effects

As in the table 6; the most frequent reported side effects in the study was dizziness, sleepiness and headache. The incidence of these side effects was significantly ($p < 0.05$) higher in Imipramine group. Sleep disturbances; nightmares, also occur more significantly ($p < 0.05$) in imipramine group. While incidence of urinary retention and constipation were lower and imipramine group was not significant ($p < 0.05$) different from that of control.

Table 1: Age smoking years; and average nicotine and tar concentration per cigarette; for groups of the study. some of data expressed as Mean \pm standard deviation

	Control Group N=51	imipramine N=102	P values
Age (years)	30.5 \pm 10.7	30.7 \pm 11.5	0.923
Age Range	20-56	16-73	
Years of smoking	11 \pm 6.5	9.4 \pm 8.3	0.2312
Smoking duration range (years)	3-29	1-35	
Average nicotine (mg) per cigarette	0.26 \pm 0.15	0.32 \pm 0.24	0.0507
Average tar (mg) per cigarette	2.6 \pm 1.55	2.7 \pm 1.83	0.6956

Table 2: average daily cigarettes smoked during the study. Data expressed as Mean \pm standard deviation

	Control Group N=51	Imipramine N=102	P values
Day1	22.76 \pm 5.83	21.08 \pm 10.47	<0.0001
Day2	24.27 \pm 6.65	19.74 \pm 9.87	
Day3	23.88 \pm 7.03	18.5 \pm 8.84	
Day4	24.24 \pm 6.91	17.84 \pm 8.39	
Day5	24.47 \pm 6.32	16.73 \pm 8.07	
Day6	22.94 \pm 7.05	15.66 \pm 8.5	
Day7	23.86 \pm 7.2	14.48 \pm 8.55	
Day8	23.55 \pm 6.89	13.7 \pm 8.56	
Day9	25.65 \pm 6.39	13.45 \pm 8.64	
Day10	23.1 \pm 6.91	12.92 \pm 8.3	
p- value	0.593	< 0.0001	




Figure 1: Shows changes in the reported daily number of smoked cigarettes in study groups. The declining was clear in imipramine group

Table 3: Comparison between the reported numbers of cigarettes smoked in day 1 and day10 of study. Data expressed as Mean± standard deviation

	Number of cigarettes smoked		P values
	Control Group N=51	Imipramine N=102	
Day1	22.76 ± 5.83	21.08 ± 10.47	0.2033
Day10	23.1 ± 6.91	12.92 ± 8.3 ^a	<0.0001
P value	0.2936	<0.0001	

*Significant (p<0.05) as compared with day1 values
A Significant (p<0.05) as compared with control group




Figure 2: Shows difference between number of cigarettes smoked in 1st and 10th day in study groups. In which the declining was clear in imipramine group

Table 4: Comparison between percent decline in cigarettes smoked measured in day 10 and as total change in study groups when compared with baseline values. Data expressed as Mean \pm standard deviation.

	Percent Declining		P values
	Control group N=51	Imipramine group N=102	
Day10	5.87 \pm 34.1 95% CI -3.7 to 15.4	-38 \pm 35.1 95% CI -44.8 to -31.1	<0.0001
All over change	7.33 \pm 16.3 95% CI 2.7 to 11.9	-20.95 \pm 20.5 95% CI -24.9 to -16.9	<0.0001
95% CI = 95% confidence interval for mean			

Table 5: Comparison between number & percentage of volunteers show positive outcome (declining in number of cigarettes smoked)

	Control group N=51	Imipramine group N=102	P values
Day10	31 (60.8%)	99(97.1%)	<0.0001
All over change	12 (23.5%)	96(94.1%)	<0.0001
Complete abstinence	0(0.0%)	12(11.8%)	0.0256
Odd ratio	52	95% CI 18.228 to 148.345	<0.0001
Odd ratio >1 favor imipramine group			

Table 6: Incidence of side effects reported by groups of volunteers during the study.

	Control Group N=51	Imipramine group N=102	P values
Dizziness	18 (35.3%)	76 (74.1%)	<0.0001
Sleepy	20 (39.2%)	78 (76.5%)	<0.0001
Headache	13 (25.5%)	55 (53.9%)	0.0016
Sleep disturbance	3(5.9%)	40 (39.2%)	<0.0001
Nightmares	2 (3.9%)	23 (22.5%)	0.0068
Urinary retention	4 (7.8%)	22 (21.6%)	0.0571
Constipations	4 (7.8%)	17 (16.7%)	0.2128
Other side effects	1 (1.96%)	0(0%)	0.7228

DISCUSSION

Results of this study show clear gradual declining (see figure 1) in the reported number of cigarettes smoked after use of single daily dose of imipramine 25mg at night; and there were about 11.8% of volunteers completely stopped smoking during and at the end of study. see tables 1-5.

These results may be related to ability of tricyclic antidepressant imipramine to affect

various neurotransmitters in brain; [23] the complexity of effects of imipramine may have some degree of similarity to that induced by nicotine present in tobacco smoke. Imipramine relieves the depressed mood and may reduce the need for tobacco smoke. [12] While nicotine does so probably through stimulating release of some mediators like serotonin and norepinephrine in various area of brain and causes relieving the depression and change

in mood in smokers which happen prior to smoking cigarette. [24]

Cigarettes abstinence ratio in this study was smaller than the reported by other antidepressants like nortriptyline and bupropion (nortriptyline 30.8% and bupropion 41.5%) [25] and imipramine 75 mg daily [12] this may be related to short period of study (ten days versus 6 months for other studies), but these results may be promising.

Rates of reported side effects induced by imipramine in this study arranged in descending order were sleepiness, dizziness, headache, sleep disturbance, nightmare, urinary retention and constipation. These were comparable with the reported by F.M. Haggstra *et al.* 2006 [25]. These side effects were well tolerated by volunteers and all of them complete the study of ten days. These side effects were not different from the reported in the drug literature [26].

CONCLUSIONS

Imipramine (Tofranil®), in dose 25 mg given once at night may result in declining of number of daily cigarettes smoked, and may help in stop this habit.

ACKNOWLEDGEMENT

Esam F. Alamiri; Sabrin Wally, Ridha Mohammed, Nada Abdulimam and all the others who helped complete the study.

CONFLICT OF INTEREST

There is no conflict of interest; and the research is self-funded by researcher himself.

Funding source

The research was funded by researcher himself

This original article; and the trial was approved by scientific and ethical committee in college of pharmacy-university of Basra

All volunteers in this trial agreed to go within trial after explaining the purpose of trial and side effects of drugs used and then asked them to sign the written consent

REFERENCES

- [1] Sibin P Saha, Deepak K Bhalla, Thomas F Whayne, Jr CG Gairola. *Int J Angiol*, 2007 Autumn; 16(3): 77–83.
- [2] Ali Ramazan Benli, Selman Erturhan, Muhammet Ali Oruc, Pinar Kalpakci, *et al.* *Tobacco Induced Diseases*, 2017; 15:10-18
- [3] Suchitra Krishnan-Sarin, Brady Reynolds, Amy M. Duhig, Anne Smith *et al.* *Drug and Alcohol Dependence*, 2007; 88: 79–82.
- [4] Mark J. Eisenberg, Kristian B. Filion, *et al.* *CMAJ*, 2008; 179(2): 2

- [5] Thomas E. Kottke, Renaldo N. Battista, Gordon H. DeFriese, et.al. JAMA, 1988;259(19):2882-2889.
- [6] C S Paulose, K Dakshinamurti, S Packer, N L Stephens. Hypertension, 1988; 11:387-391.
- [7] Picciotto, M.R., Mineur, Y.S. Neuropharmacology, 2014; 76B: 545–553
- [8] Joanna S. Fowler, Nora D. Volkow, Gene-Jack Wang, Naomi Pappas, et. al. Natl. Acad. Sci, 1996 (93):14065–14069
- [9] Cahill K, Lancaster T, Perera R. Cochrane Database of Systematic Reviews, 2011, Issue 9. Art. No.: CD009329.
- [10] Cahill K, Stevens S, Perera R, Lancaster T. Cochrane Database of Systematic Reviews, 2013; Issue 5. Art.No.: CD009329. DOI: 10.1002/14651858.CD009329.pub 2.
- [11] Paul Aveyard, Robert West. BMJ 2007;335:37-41
- [12] Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Cochrane Database of Systematic Reviews, 2014; Issue 1. Art. No.: CD000031.
- [13] Stead LF, Lancaster T. Cochrane Database of Systematic Reviews 2012, Issue 10. Art. No.: CD008286.
- [14] Chen, F., Madsen, T. M., Wegener, G. and Nyengaard, J. R. Hippocampus, 2010; 20: 1376–1384.
- [15] Attal, N., Cruccu, G., Baron, R., Haanpää, M., Hansson, P., Jensen, T. S. and Nurmikko, T. European Journal of Neurology, 2010; 17: 1113–e88.
- [16] Mehdi Abedin Zadeh, Mohammad Kazem Moslemi, Golrasteh Kholaseh Zadeh. Journal of Pediatric Urology, 2011; (7), 30–33
- [17] Tatsumi M, Groshan K, Blakely RD, Richelson E. *Eur. J. Pharmacol*, 1997; 340 (2-3): 249–58.
- [18] Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. *J. Pharmacol. Exp. Ther*, 1997; 283 (3): 1305–22.
- [19] Smiałowski, A. *Pharmacology, Biochemistry, and Behavior*, 1991; 39 (1): 105–108.
- [20] Cusack B, Nelson A, Richelson E. *Psychopharmacology*, 1994; 114(4): 559–65. PMID 7855217.
- [21] Stanton T, Bolden-Watson C, Cusack B, Richelson E. *Biochem. Pharmacol*, 1993; 45 (11): 2352–4.

-
- [22] Bernadette Cusack, Albert Nelson, Elliott Richelson. *Psychopharmacology*,1994;114: 559,-565
- [23] Imipramine. Wikipedia free online encyclopedia.
<https://en.wikipedia.org/wiki/Imipramine> . accessed 16 sept; 2017
- [24] JesperT.AndreasenJohnP.Redrobe. *Behavioural Brain Research*,2009(197): 150–156
- [25] Fa 'bio M.Haggstra 'm, Jose ' M. Chatkin, Eliana Sussenbach-Vaz, De 'bora H. *et al.* *Pulmonary Pharmacology & Therapeutics* ,2006; 19:205–209.
- [26] Tofranil.<http://www.rxlist.com/tofranal-drug.html>. Accessed on 16 sept; 2017